PMID- 33950404
OWN - NLM
STAT- MEDLINE
DCOM- 20220110
LR  - 20230328
IS  - 1573-2606 (Electronic)
IS  - 1389-9155 (Print)
IS  - 1389-9155 (Linking)
VI  - 22
IP  - 4
DP  - 2021 Dec
TI  - New aspects in the pathogenesis and management of subacute thyroiditis.
PG  - 1027-1039
LID - 10.1007/s11154-021-09648-y [doi]
AB  - Subacute thyroiditis (SAT) is a thyroid inflammatory disease, whose pathogenesis 
      and determinants of the clinical course were unclear for many decades. The last 
      few years have brought many clinically significant new data on the epidemiology, 
      pathogenesis and management of SAT. Several human leukocyte antigen (HLA) alleles 
      were demonstrated not only to increase the risk of SAT, but also to correlate 
      with SAT clinical course and determine the risk of recurrence. The world-wide 
      epidemic of the coronavirus disease 19 (COVID-19) has provided new observations 
      that the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can be a 
      potent SAT-triggering factor, and that the clinical course of SAT in patients 
      affected by COVID-19 is different from a typical one. Additionally, many new 
      trends in the clinical course are emerging. In the last years, painless course of 
      SAT is more and more often described, constituting a special challenge in 
      patients hospitalized due to COVID-19. Despite an excellent availability of 
      diagnostic methods, several difficulties in SAT differential diagnosis can be 
      currently encountered and the proper diagnosis and treatment is frequently 
      delayed. False positive diagnoses of SAT in patients with malignancies of poor 
      prognosis constitute a life-threatening problem. Taking into account all the new 
      aspects of SAT pathogenesis and of its clinical course, the new - modified - SAT 
      diagnosis criteria have been proposed.
CI  - (c) 2021. The Author(s).
FAU - Stasiak, Magdalena
AU  - Stasiak M
AUID- ORCID: 0000-0002-2910-7691
AD  - Department of Endocrinology and Metabolic Diseases, Polish Mother's Memorial 
      Hospital, Research Institute, 281/289 Rzgowska St, 93-338, Lodz, Poland.
FAU - Lewinski, Andrzej
AU  - Lewinski A
AUID- ORCID: 0000-0002-8748-3337
AD  - Department of Endocrinology and Metabolic Diseases, Polish Mother's Memorial 
      Hospital, Research Institute, 281/289 Rzgowska St, 93-338, Lodz, Poland. 
      andrzej.lewinski@umed.lodz.pl.
AD  - Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, 
      281/289 Rzgowska St., 93-338, Lodz, Poland. andrzej.lewinski@umed.lodz.pl.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20210505
PL  - Germany
TA  - Rev Endocr Metab Disord
JT  - Reviews in endocrine & metabolic disorders
JID - 100940588
SB  - IM
MH  - *COVID-19
MH  - Humans
MH  - SARS-CoV-2
MH  - *Thyroid Diseases
MH  - *Thyroiditis, Subacute/diagnosis/epidemiology/therapy
PMC - PMC8096888
OTO - NOTNLM
OT  - COVID-19
OT  - Clinical course
OT  - HLA
OT  - Recurrence
OT  - SARS-CoV-2
OT  - Subacute thyroiditis
COIS- The authors declare no conflict of interest.
EDAT- 2021/05/06 06:00
MHDA- 2022/01/11 06:00
PMCR- 2021/05/05
CRDT- 2021/05/05 12:38
PHST- 2021/03/18 00:00 [accepted]
PHST- 2021/05/06 06:00 [pubmed]
PHST- 2022/01/11 06:00 [medline]
PHST- 2021/05/05 12:38 [entrez]
PHST- 2021/05/05 00:00 [pmc-release]
AID - 10.1007/s11154-021-09648-y [pii]
AID - 9648 [pii]
AID - 10.1007/s11154-021-09648-y [doi]
PST - ppublish
SO  - Rev Endocr Metab Disord. 2021 Dec;22(4):1027-1039. doi: 
      10.1007/s11154-021-09648-y. Epub 2021 May 5.